Survival among patients with and without Down syndrome enrolled on Children's Cancer Group acute lymphoblastic leukemia studies from 1983 to 1995
. | Entire cohort . | . | . | Standard risk . | . | . | High risk . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | ALL-DS, % . | ALL-NDS, % . | P . | ALL-DS, % . | ALL-NDS, % . | P . | ALL-DS, % . | ALL-NDS, % . | P . | ||||||
| Entire cohort | |||||||||||||||
| Overall survival, 10 y | 68.13 ± 3.9 | 77.24 ± 0.5 | <.001 | 70.17 ± 4.9 | 84.87 ± 0.6 | <.001 | 63.32 ± 7.1 | 65.49 ± 1 | .7 | ||||||
| Event-free survival, 10 y | 55.48 ± 4.7 | 67.95 ± 6 | .007 | 56.29 ± 6 | 73.48 ± 0.7 | <.001 | 62.06 ± 6.5 | 59.29 ± 0.9 | .9 | ||||||
| Disease-free survival, 10 y | 54.35 ± 5 | 67.23 ± 0.6 | .001 | 54.59 ± 6.5 | 72.48 ± 0.8 | <.001 | 63.51 ± 6.7 | 58.98 ± 1 | .9 | ||||||
| Early era: 100 series | |||||||||||||||
| Event-free survival, 10 y | 43.33 ± 5.8 | 62.23 ± 0.8 | <.001 | 43.36 ± 7.5 | 68.13 ± 1.1 | <.001 | 51.59 ± 9.7 | 53.28 ± 1.4 | .6 | ||||||
| Recent era: 1800 series | |||||||||||||||
| Event-free survival, 5 y | 71.62 ± 4.6 | 73.20 ± 0.8 | .3 | 73.66 ± 5.4 | 81.48 ± 0.8 | .04 | 72.92 ± 7.7 | 66.96 ± 1.1 | .5 | ||||||
. | Entire cohort . | . | . | Standard risk . | . | . | High risk . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | ALL-DS, % . | ALL-NDS, % . | P . | ALL-DS, % . | ALL-NDS, % . | P . | ALL-DS, % . | ALL-NDS, % . | P . | ||||||
| Entire cohort | |||||||||||||||
| Overall survival, 10 y | 68.13 ± 3.9 | 77.24 ± 0.5 | <.001 | 70.17 ± 4.9 | 84.87 ± 0.6 | <.001 | 63.32 ± 7.1 | 65.49 ± 1 | .7 | ||||||
| Event-free survival, 10 y | 55.48 ± 4.7 | 67.95 ± 6 | .007 | 56.29 ± 6 | 73.48 ± 0.7 | <.001 | 62.06 ± 6.5 | 59.29 ± 0.9 | .9 | ||||||
| Disease-free survival, 10 y | 54.35 ± 5 | 67.23 ± 0.6 | .001 | 54.59 ± 6.5 | 72.48 ± 0.8 | <.001 | 63.51 ± 6.7 | 58.98 ± 1 | .9 | ||||||
| Early era: 100 series | |||||||||||||||
| Event-free survival, 10 y | 43.33 ± 5.8 | 62.23 ± 0.8 | <.001 | 43.36 ± 7.5 | 68.13 ± 1.1 | <.001 | 51.59 ± 9.7 | 53.28 ± 1.4 | .6 | ||||||
| Recent era: 1800 series | |||||||||||||||
| Event-free survival, 5 y | 71.62 ± 4.6 | 73.20 ± 0.8 | .3 | 73.66 ± 5.4 | 81.48 ± 0.8 | .04 | 72.92 ± 7.7 | 66.96 ± 1.1 | .5 | ||||||
ALL-DS indicates patients with both acute lymphoblastic leukemia (ALL) and Down syndrome (DS); ALL-NDS denotes patients with ALL but without Down syndrome.